A team of dedicated humanns.
Executive Leadership Team
Michael Castagna, PharmD
Chief Executive Officer
Michael Castagna, PharmD
Chief Executive Officer
Michael Castagna became CEO of MannKind Corporation and joined the company’s board of directors in 2017, bringing more than 25 years’ experience in healthcare, pharmaceuticals and biotechnology to the company's product and medical device development strategy. Under his guidance, MannKind is successfully establishing solid partnerships and growing its pipeline, capitalizing on Michael's extensive knowledge of the commercial pharmaceutical industry. Michael’s deep understanding of the biopharmaceutical industry and dedication to helping people live their lives without limits is grounded by his extensive pharmacy background.
Previously, Michael served as a Vice President at Amgen, guiding both the Lifecycle Management and Global Commercial Biosimilar business areas of the company. Before Amgen, he spent a combined 10 years at Bristol-Myers Squibb, focusing on medical, marketing and sales from 1997 to 2005, returning to the company in 2010 to direct the Immunoscience division from 2010 to 2012. Other industry experience includes serving as a Vice President at Sandoz, as well as a Director at both Merck, Serono and Pharmasset.
When he's not focusing on company strategy and operations or how to make innovative new treatments available to people living with diabetes and orphan lung diseases, Michael spends time traveling with his family, scuba diving, and visiting car events.
Michael Castagna became CEO of MannKind Corporation and joined the company’s board of directors in 2017, bringing more than 25 years’ experience in healthcare, pharmaceuticals and biotechnology to the company's product and medical device development strategy. Under his guidance, MannKind is successfully establishing solid partnerships and growing its pipeline, capitalizing on Michael's extensive knowledge of the commercial pharmaceutical industry. Michael’s deep understanding of the biopharmaceutical industry and dedication to helping people live their lives without limits is grounded by his extensive pharmacy background.
Previously, Michael served as a Vice President at Amgen, guiding both the Lifecycle Management and Global Commercial Biosimilar business areas of the company. Before Amgen, he spent a combined 10 years at Bristol-Myers Squibb, focusing on medical, marketing and sales from 1997 to 2005, returning to the company in 2010 to direct the Immunoscience division from 2010 to 2012. Other industry experience includes serving as a Vice President at Sandoz, as well as a Director at both Merck, Serono and Pharmasset.
When he's not focusing on company strategy and operations or how to make innovative new treatments available to people living with diabetes and orphan lung diseases, Michael spends time traveling with his family, scuba diving, and visiting car events.
Chris Prentiss
Chief Financial Officer
Chris Prentiss
Chief Financial Officer
Chris Prentiss guides the financial strategy for the company, drawing on nearly 20 years of biotech
industry experience with both private and public companies. A successful executive in financial and
accounting, he is focused on delivering on corporate goals, building shareholder value, and helping drive
MannKind’s mission
Chris joined MannKind in 2024 after serving as Chief Financial Officer of ADARx Pharmaceuticals, Inc.,
where he helped raise nearly $250 million in funding. Prior to that he spent six years with Adamas
Pharmaceuticals where he held a series of senior finance positions of increasing responsibility that
culminated with CFO. Chris was first introduced to the biopharmaceutical arena in 2005 when he first
joined MannKind; he initially spent six-plus years with the company, including as its Corporate
Controller.
In his down time, Chris enjoys spending time with his family – particularly outdoor adventures from
biking, hiking, going to the beach, and soccer.
Chris Prentiss guides the financial strategy for the company, drawing on nearly 20 years of biotech
industry experience with both private and public companies. A successful executive in financial and
accounting, he is focused on delivering on corporate goals, building shareholder value, and helping drive
MannKind’s mission
Chris joined MannKind in 2024 after serving as Chief Financial Officer of ADARx Pharmaceuticals, Inc.,
where he helped raise nearly $250 million in funding. Prior to that he spent six years with Adamas
Pharmaceuticals where he held a series of senior finance positions of increasing responsibility that
culminated with CFO. Chris was first introduced to the biopharmaceutical arena in 2005 when he first
joined MannKind; he initially spent six-plus years with the company, including as its Corporate
Controller.
In his down time, Chris enjoys spending time with his family – particularly outdoor adventures from
biking, hiking, going to the beach, and soccer.
Lauren Sabella
Executive Vice President, Chief Operating Officer
Lauren Sabella
Executive Vice President, Chief Operating Officer
Lauren Sabella joined as EVP, COO in 2023, bringing to her role a wealth of commercial, respiratory, and operational experience in the healthcare industry. She oversees MannKind’s critical functions that operate in Danbury in both the endocrine and orphan lung areas of the business.
Lauren came to MannKind after 12 years at Acorda Therapeutics first as Chief Commercial Officer and finishing as COO. Lauren also spent 18 years at Boehringer Ingelheim Pharmaceuticals where she successfully launched two products that each surpassed $1 billion in sales.
Having lived in Connecticut for the last 30 years, Lauren is an avid participant with local charitable initiatives. She enjoys focusing on a healthy lifestyle with yoga, meditation and regular fitness such as kayaking along the Long Island Sound. Lauren also has a love for watching the NFL, travel, and social time with family and friends.
Lauren Sabella joined as EVP, COO in 2023, bringing to her role a wealth of commercial, respiratory, and operational experience in the healthcare industry. She oversees MannKind’s critical functions that operate in Danbury in both the endocrine and orphan lung areas of the business.
Lauren came to MannKind after 12 years at Acorda Therapeutics first as Chief Commercial Officer and finishing as COO. Lauren also spent 18 years at Boehringer Ingelheim Pharmaceuticals where she successfully launched two products that each surpassed $1 billion in sales.
Having lived in Connecticut for the last 30 years, Lauren is an avid participant with local charitable initiatives. She enjoys focusing on a healthy lifestyle with yoga, meditation and regular fitness such as kayaking along the Long Island Sound. Lauren also has a love for watching the NFL, travel, and social time with family and friends.
Steven Binder
Executive Vice President, Special Projects
Steven Binder
Executive Vice President, Special Projects
Steve serves as Executive Vice President, Special Projects at MannKind (until his retirement in December 2024) following seven years as the company’s Chief Financial Officer. A leading global financial executive with broad international experience, Steve joined the company in 2017, crafting a robust financial plan to steer MannKind's future growth, product development, and expansion of the Company’s innovative technology.
Steven Binder's biomedical finance career includes Chief Financial Officer at Stryker International, a leader in medical technology development, where he transformed the company's international finance function. Prior to Stryker, he spent 21 years at Bristol-Myers Squibb (BMS) as its Vice President of Finance providing financial and business leadership to teams worldwide while living in three countries outside the U.S. He began his career at Deloitte & Touche as a certified public accountant.
An avid sportsman, Steven Binder actively hikes, mountain bikes and plays golf. He was named "Public Company CFO of the Year 2020" by the Los Angeles Business Journal and "Large Public Company CFO of the Year" by San Fernando Valley Business Journal in 2020.
Steve serves as Executive Vice President, Special Projects at MannKind (until his retirement in December 2024) following seven years as the company’s Chief Financial Officer. A leading global financial executive with broad international experience, Steve joined the company in 2017, crafting a robust financial plan to steer MannKind's future growth, product development, and expansion of the Company’s innovative technology.
Steven Binder's biomedical finance career includes Chief Financial Officer at Stryker International, a leader in medical technology development, where he transformed the company's international finance function. Prior to Stryker, he spent 21 years at Bristol-Myers Squibb (BMS) as its Vice President of Finance providing financial and business leadership to teams worldwide while living in three countries outside the U.S. He began his career at Deloitte & Touche as a certified public accountant.
An avid sportsman, Steven Binder actively hikes, mountain bikes and plays golf. He was named "Public Company CFO of the Year 2020" by the Los Angeles Business Journal and "Large Public Company CFO of the Year" by San Fernando Valley Business Journal in 2020.
Burkhard Blank, MD
Executive Vice President, Research & Development and Chief Medical Officer
Burkhard Blank, MD
Executive Vice President, Research & Development and Chief Medical Officer
Dr. Burkhard Blank joined MannKind in 2023, bringing more than 25 years of broad managerial experience and global drug development across all clinical, medical, and regulatory disciplines in multiple disease areas. He has consolidated responsibility for MannKind’s research & development, regulatory, and medical groups.
Prior to MannKind, Dr. Blank served as CMO/Head of R&D for Pharnext SA after serving seven years in the same position at Acorda Therapeutics. Earlier in his career, Dr. Blank spent 20 years between Boehringer Ingelheim Pharmaceuticals in CT and Boehringer Ingelheim GmbH in Germany. He has deep knowledge in the inhaled therapeutics space and was instrumental in eight NDA and MAA submissions for small molecules, biologics, and drug-device combinations.
An avid music fan, Burkhard enjoys spending time with his family, fishing and sailing
Dr. Burkhard Blank joined MannKind in 2023, bringing more than 25 years of broad managerial experience and global drug development across all clinical, medical, and regulatory disciplines in multiple disease areas. He has consolidated responsibility for MannKind’s research & development, regulatory, and medical groups.
Prior to MannKind, Dr. Blank served as CMO/Head of R&D for Pharnext SA after serving seven years in the same position at Acorda Therapeutics. Earlier in his career, Dr. Blank spent 20 years between Boehringer Ingelheim Pharmaceuticals in CT and Boehringer Ingelheim GmbH in Germany. He has deep knowledge in the inhaled therapeutics space and was instrumental in eight NDA and MAA submissions for small molecules, biologics, and drug-device combinations.
An avid music fan, Burkhard enjoys spending time with his family, fishing and sailing
Sanjay Singh, MPharm, MBA
Executive Vice President, Technical Operations MannKind
Sanjay Singh, MPharm, MBA
Executive Vice President, Technical Operations MannKind
Sanjay Singh is Executive Vice President of MannKind’s Technical Operations, leading our Danbury facility including oversight of our commercial and contract manufacturing. With more than 30 years of experience in pharmaceutical technical operations, he has worked with multiple technologies, delivery systems, and therapeutic areas.
Prior to joining MannKind in 2022, Sanjay was Associate President of Operations for Aurobindo Pharma USA having moved stateside after serving as Senior VP of Operations for Aurobindo Pharma India. He also held positions of increasing responsibility at Cipla Ltd, Glenmark Pharmaceuticals, Nicholas Piramal India Ltd, and Cadila Laboratories.
Sanjay grew up in Indore, India, and earned both is MPharm and MBA in country. He has managed technical projects in three countries – India, China, and the U.S. – and speaks two languages. Away from the office he enjoys time cooking for his family and friends, watching cricket, and reading technical journals to stay abreast of the latest industry developments.
Sanjay Singh is Executive Vice President of MannKind’s Technical Operations, leading our Danbury facility including oversight of our commercial and contract manufacturing. With more than 30 years of experience in pharmaceutical technical operations, he has worked with multiple technologies, delivery systems, and therapeutic areas.
Prior to joining MannKind in 2022, Sanjay was Associate President of Operations for Aurobindo Pharma USA having moved stateside after serving as Senior VP of Operations for Aurobindo Pharma India. He also held positions of increasing responsibility at Cipla Ltd, Glenmark Pharmaceuticals, Nicholas Piramal India Ltd, and Cadila Laboratories.
Sanjay grew up in Indore, India, and earned both is MPharm and MBA in country. He has managed technical projects in three countries – India, China, and the U.S. – and speaks two languages. Away from the office he enjoys time cooking for his family and friends, watching cricket, and reading technical journals to stay abreast of the latest industry developments.
David Thomson, PhD, JD
General Counsel and Corporate Secretary
David Thomson, PhD, JD
General Counsel and Corporate Secretary
David Thomson started in 2000 before the three-way merger that created MannKind Corporation from CTL ImmunoTherapies Corp., AlleCure Corp. and Pharmaceutical Development Corporation, all of which were majority-owned by Alfred Mann. Since then, he has been responsible for the company’s legal affairs, compliance matters, patents, and global business development activities as a member of the executive leadership team.
David, who holds a Ph.D. in neuroscience and is the longest-serving MannKind employee, understands the importance of building upon Al’s legacy of helping people live fuller lives without limit. Prior to MannKind, David was an associate at Toronto-based Davies Ward Phillips & Vineberg LLP. He earned his Juris Doctor degree from the University of Toronto.
In addition to playing a leading role in MannKind's growth through the development of strategic alliances, David feeds his love of soccer by volunteering for the American Youth Soccer Organization.
David Thomson started in 2000 before the three-way merger that created MannKind Corporation from CTL ImmunoTherapies Corp., AlleCure Corp. and Pharmaceutical Development Corporation, all of which were majority-owned by Alfred Mann. Since then, he has been responsible for the company’s legal affairs, compliance matters, patents, and global business development activities as a member of the executive leadership team.
David, who holds a Ph.D. in neuroscience and is the longest-serving MannKind employee, understands the importance of building upon Al’s legacy of helping people live fuller lives without limit. Prior to MannKind, David was an associate at Toronto-based Davies Ward Phillips & Vineberg LLP. He earned his Juris Doctor degree from the University of Toronto.
In addition to playing a leading role in MannKind's growth through the development of strategic alliances, David feeds his love of soccer by volunteering for the American Youth Soccer Organization.
Stuart Tross, PhD
Chief People and Workplace Officer
Stuart Tross, PhD
Chief People and Workplace Officer
Stuart Tross serves as MannKind's Chief People and Workplace Officer, leading human resources activities and supporting the high-performing, inclusive culture that MannKind strives to foster. Stuart also leads information technology, corporate communications, and Westlake Village office facilities management for the company.
With extensive biopharmaceutical industry experience, Stuart joined MannKind after serving as Chief Human Resources Officer at Amgen. Prior to that, he was Global Head of Human Resources for Mead Johnson Nutrition, which was owned by Bristol Myers Squibb at that time. Earlier, he held several roles in varied areas of human resources for BMS after an early career management stint at Towers Perrin (now Willis Towers Watson).
Outside of work, Stuart enjoys spending time with his family and friends watching and participating in various sports and physical activities. He proudly serves as an advisory board member for the Los Angeles Chapter of the Healthcare Businesswomen's Association.
Stuart Tross serves as MannKind's Chief People and Workplace Officer, leading human resources activities and supporting the high-performing, inclusive culture that MannKind strives to foster. Stuart also leads information technology, corporate communications, and Westlake Village office facilities management for the company.
With extensive biopharmaceutical industry experience, Stuart joined MannKind after serving as Chief Human Resources Officer at Amgen. Prior to that, he was Global Head of Human Resources for Mead Johnson Nutrition, which was owned by Bristol Myers Squibb at that time. Earlier, he held several roles in varied areas of human resources for BMS after an early career management stint at Towers Perrin (now Willis Towers Watson).
Outside of work, Stuart enjoys spending time with his family and friends watching and participating in various sports and physical activities. He proudly serves as an advisory board member for the Los Angeles Chapter of the Healthcare Businesswomen's Association.
Board of Directors
James Shannon
James Shannon
Joined
May 2015 (also served February 2010–April 2012)
Current Role
Chairman of the Board
Compensation Committee member
Current Experience
Director: Kyowa Kirin (NA)
Director: Immodulon Therapeutics Limited
Director: ProQR Therapeutics NV
Director: MyTommorows
Past Experience
Director: Horizon Therapeutics plc
Chief Medical Officer: GlaxoSmithKline
Global Head of Pharma Development: Novartis AG
Director: Biotie
Director: Circassia
Director: Crucell
Director: Endocyte
Director, Interim Chief Executive Officer: Cerimon Pharmaceuticals
Education
Queen’s University of Belfast: undergraduate and postgraduate degrees in medicine and cardiology
Joined
May 2015 (also served February 2010–April 2012)
Current Role
Chairman of the Board
Compensation Committee member
Current Experience
Director: Kyowa Kirin (NA)
Director: Immodulon Therapeutics Limited
Director: ProQR Therapeutics NV
Director: MyTommorows
Past Experience
Director: Horizon Therapeutics plc
Chief Medical Officer: GlaxoSmithKline
Global Head of Pharma Development: Novartis AG
Director: Biotie
Director: Circassia
Director: Crucell
Director: Endocyte
Director, Interim Chief Executive Officer: Cerimon Pharmaceuticals
Education
Queen’s University of Belfast: undergraduate and postgraduate degrees in medicine and cardiology
Ronald Consiglio
Ronald Consiglio
Joined
October 2003
Current Roles
Audit Committee chair
Nominating and Corporate Governance Committee member
Current Experience
Managing Director: Synergy Trading
Trustee: Metropolitan West Funds
Past Experience
Executive Vice President and Chief Financial Officer: Trading Edge, Inc.
Chief Executive Officer: Angeles Mortgage Investment Trust
Director, Senior Vice President and Chief Financial Officer: Cantor Fitzgerald & Co.
Partner: Deloitte Haskins & Sells
Education
California State University at Northridge: B.S. (accounting)
Joined
October 2003
Current Roles
Audit Committee chair
Nominating and Corporate Governance Committee member
Current Experience
Managing Director: Synergy Trading
Trustee: Metropolitan West Funds
Past Experience
Executive Vice President and Chief Financial Officer: Trading Edge, Inc.
Chief Executive Officer: Angeles Mortgage Investment Trust
Director, Senior Vice President and Chief Financial Officer: Cantor Fitzgerald & Co.
Partner: Deloitte Haskins & Sells
Education
California State University at Northridge: B.S. (accounting)
Michael Friedman
Michael Friedman
Joined
December 2003
Current Roles
Nominating and Corporate Governance Committee member
Experience
President and Chief Executive Officer: City of Hope National Medical Center
Senior Vice President: Pharmacia Corporation
Senior Vice President: Searle, a subsidiary of Monsanto Company
Acting Commissioner and Lead Deputy Commissioner: Food and Drug Administration
Director: Celgene Corporation
Director: Smith & Nephew plc
Education
Tulane University: B.A., magna cum laude
University of Texas, Southwestern Medical School: M.D.
Joined
December 2003
Current Roles
Nominating and Corporate Governance Committee member
Experience
President and Chief Executive Officer: City of Hope National Medical Center
Senior Vice President: Pharmacia Corporation
Senior Vice President: Searle, a subsidiary of Monsanto Company
Acting Commissioner and Lead Deputy Commissioner: Food and Drug Administration
Director: Celgene Corporation
Director: Smith & Nephew plc
Education
Tulane University: B.A., magna cum laude
University of Texas, Southwestern Medical School: M.D.
Jennifer Grancio
Jennifer Grancio
Joined
March 2020
Current Role
Audit Committee member
Nominating and Corporate Governance Committee chair
Current Experience
Global Head of Wealth: The TCW Group
Director: Ethic Inc.
Director: Harvest Savings & Wealth Technologies, Inc.
Past Experience
Managing Director, Head of Global Business Development, iShares: BlackRock
Senior Associate, Financial Services Management Consulting: PricewaterhouseCoopers
Education
Stanford University: B.A. (economics and international relations)
Columbia Business School: MBA (strategy and finance)
Joined
March 2020
Current Role
Audit Committee member
Nominating and Corporate Governance Committee chair
Current Experience
Global Head of Wealth: The TCW Group
Director: Ethic Inc.
Director: Harvest Savings & Wealth Technologies, Inc.
Past Experience
Managing Director, Head of Global Business Development, iShares: BlackRock
Senior Associate, Financial Services Management Consulting: PricewaterhouseCoopers
Education
Stanford University: B.A. (economics and international relations)
Columbia Business School: MBA (strategy and finance)
Anthony Hooper
Anthony Hooper
Joined
January 2020
Current Role
Audit Committee member
Compensation Committee Chair
Current Experience
Director: BeiGene Ltd.
Director: Amplity Health
Past Experience
Executive Vice President, Global Commercial Operations: Amgen Inc.
Senior Vice President, Global Commercial Operations: Bristol-Myers Squibb
Assistant Vice President, Global Marketing: Wyeth Laboratories
Education
University of South Africa: law and MBA degrees
Joined
January 2020
Current Role
Audit Committee member
Compensation Committee Chair
Current Experience
Director: BeiGene Ltd.
Director: Amplity Health
Past Experience
Executive Vice President, Global Commercial Operations: Amgen Inc.
Senior Vice President, Global Commercial Operations: Bristol-Myers Squibb
Assistant Vice President, Global Marketing: Wyeth Laboratories
Education
University of South Africa: law and MBA degrees
Sabrina Kay
Sabrina Kay
Joined:
December 2020
Current Role
Audit Committee member
Compensation Committee member
Current Experience
Chief Executive Officer: Fremont Private Investments
Strategic Partner: VSS Capital Partners
Chairman: After-School All-Stars Los Angeles
Director: East West Bank (NASDAQ: EWBC), Hagerty (NYSE:HGTY)
Past Experience
Chief Executive Officer: Fremont College
Founder and CEO: The Art Institute of Hollywood
Co-Founder and Vice-Chairman: Premier Business Bank
Founder and CEO: Fashion Umbrella
Chief Executive Officer: Dale Carnegie of Los Angeles
Education
University of Southern California: MBA
University of Pennsylvania: M.S.
University of Pennsylvania: Ed.D.
Joined:
December 2020
Current Role
Audit Committee member
Compensation Committee member
Current Experience
Chief Executive Officer: Fremont Private Investments
Strategic Partner: VSS Capital Partners
Chairman: After-School All-Stars Los Angeles
Director: East West Bank (NASDAQ: EWBC), Hagerty (NYSE:HGTY)
Past Experience
Chief Executive Officer: Fremont College
Founder and CEO: The Art Institute of Hollywood
Co-Founder and Vice-Chairman: Premier Business Bank
Founder and CEO: Fashion Umbrella
Chief Executive Officer: Dale Carnegie of Los Angeles
Education
University of Southern California: MBA
University of Pennsylvania: M.S.
University of Pennsylvania: Ed.D.
Kent Kresa
Kent Kresa
Joined
June 2004
Current Roles
Compensation Committee member
Current Experience
Chairman and Director: Quantum Digital Solutions Corporation
Director: Systems & Technology Research
Trustee: California Institute of Technology
Past Experience
Chairman Emeritus, Chief Executive Officer: Northrop Grumman Corporation
Chairman and Director: General Motors Company
Director: Fluor Corporation
Director: Avery Dennison Corporation
Education
Massachusetts Institute of Technology: B.S., M.S. and E.A.A. (all aeronautics and astronautics)
Joined
June 2004
Current Roles
Compensation Committee member
Current Experience
Chairman and Director: Quantum Digital Solutions Corporation
Director: Systems & Technology Research
Trustee: California Institute of Technology
Past Experience
Chairman Emeritus, Chief Executive Officer: Northrop Grumman Corporation
Chairman and Director: General Motors Company
Director: Fluor Corporation
Director: Avery Dennison Corporation
Education
Massachusetts Institute of Technology: B.S., M.S. and E.A.A. (all aeronautics and astronautics)
Christine Mundkur
Christine Mundkur
Joined
November 2018
Current Role
Audit Committee member
Nominating and Corporate Governance Committee member
Current Experience
Director: Cardinal Health
Past Experience
Chief Executive Officer and non-voting Chairman: Impopharma Inc.
President and Chief Executive Officer (U.S. Division): Sandoz, Inc.
Chief Executive Officer: Barr Laboratories, Inc.
Education
St. Louis University: B.S. (chemistry)
St. Louis University School of Law: J.D.
Joined
November 2018
Current Role
Audit Committee member
Nominating and Corporate Governance Committee member
Current Experience
Director: Cardinal Health
Past Experience
Chief Executive Officer and non-voting Chairman: Impopharma Inc.
President and Chief Executive Officer (U.S. Division): Sandoz, Inc.
Chief Executive Officer: Barr Laboratories, Inc.
Education
St. Louis University: B.S. (chemistry)
St. Louis University School of Law: J.D.
Michael Castagna
Michael Castagna
Joined
May 2017
Current Role
Chief Executive Officer, MannKind Corporation
Past Experience
Chief Commercial Officer: MannKind Corporation
Vice President, Global Commercial Lead (Biosimilar Business Unit): Amgen Inc.
Executive Director, Immunology: Bristol-Myers Squibb Company
Vice President & Head, Biopharmaceuticals, North America: Sandoz
Education
University of the Sciences-Philadelphia College of Pharmacy: B.S. (pharmacy)
Massachusetts College of Pharmacy & Sciences: Pharm.D.
Wharton School of Business: MBA
Joined
May 2017
Current Role
Chief Executive Officer, MannKind Corporation
Past Experience
Chief Commercial Officer: MannKind Corporation
Vice President, Global Commercial Lead (Biosimilar Business Unit): Amgen Inc.
Executive Director, Immunology: Bristol-Myers Squibb Company
Vice President & Head, Biopharmaceuticals, North America: Sandoz
Education
University of the Sciences-Philadelphia College of Pharmacy: B.S. (pharmacy)
Massachusetts College of Pharmacy & Sciences: Pharm.D.
Wharton School of Business: MBA
Scientific Advisory Board
Thomas Blevins, MD, FACE, ECNU, FNLA
Clinical Endocrinologist, Texas Diabetes and Endocrinology, Austin, Texas
Bruce W. Bode, MD
Atlanta Diabetes Associates
Anders L. Carlson, MD
Medical Director, International Diabetes Center Medical Director, Diabetes Education Programs, HealthPartners Medical Groups Endocrinologist, Regions Hospital & HealthPartners Clinics Associate Professor, University of Minnesota Medical School
Davida F. Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner Henry Ford Health System Division of Endocrinology, Diabetes, and Bone Disorders
Kashif Latif, MD
AM Diabetes and Endocrinology Center, Bartlett, Tennessee
Scott W. Lee, MD
Medical Director Diabetes Treatment Center Professor of Medicine, LLU School of Medicine
Philip Levin, MD
Clinical Asst Professor Johns Hopkins University School of Medicine
David Maahs, MD, PhD
Associate Director, Stanford Diabetes Research Center The Kirkwood Distinguished Packard Fellow Professor of Pediatrics and, by courtesy, of Health Research and Policy (Epidemiology) Chief of Pediatric Endocrinology Lucile Packard Children’s Hospital Stanford University, School of Medicine
Janet B. McGill, MD, MA, FACE, FACP
Professor of Medicine Division of Endocrinology, Metabolism and Lipid Research Washington University School of Medicine
A legacy of humann-focused innovation.
Alfred E. Mann was a visionary in aerospace, medical technology, and biopharmaceuticals. But his true passion was helping people. During his career, he founded 17 companies and developed breakthrough medical devices, including cardiac pacemakers, insulin pumps, cochlear implants, retinal prostheses, and other technologies that have enabled people to live fuller, healthier lives.
At MannKind we continue to approach innovation by drawing on the spirit of Al’s mission – that holds true today and into the future.
- 2004: MannKind became a public company (NASDAQ: MKND)
- 2014: Afrezza received FDA approval, becoming the only inhaled ultra rapid-acting mealtime insulin in the United States.
- 2015: Formulation commenced on Treprostinil Technosphere (TreT).
- 2018: MannKind and United Therapeutics Corporation entered into a worldwide collaboration agreement for the development and commercialization of a dry powder formulation of Treprostinil.
- 2019: Afrezza received regulatory approval in Brazil.
- 2022: Our Technosphere Technology is used in Tyvaso DPI®, which received FDA approval.
- 2022: MannKind acquired V-Go®, a once-daily wearable insulin delivery device.
KEY HISTORICAL HIGHLIGHTS:
-
2009
NDA for Technosphere insulin is submitted to the FDA.
-
2014
Technosphere insulin (now Afrezza®) receives FDA approval.
-
2016
MannKind regains commercial rights to Afrezza®
-
2018
IND for TreT submitted to FDA; Phase 1 clinical study completed
-
2020
First sale of Afrezza® in Brazil
-
2022
MannKind acquires V-Go®, once-daily wearable insulin delivery device
-
2022
MannKind’s Technosphere® Technology is used in Tyvaso DPI™ which received FDA approval